Clinical Trials Logo

Clinical Trial Summary

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single- and multiple-ascending doses of DR10624 via subcutaneous (SubQ) injection in a randomized, placebo-controlled, double-blind study.


Clinical Trial Description

This study includes 2 parts( 1 and 2). Part 1 involves a single dose of DR10624 taken as a subcutaneous injection just under the skin. Part 2 involve multiple doses of DR10624 taken as a subcutaneous injection (SC) just under the skin. Each participant will enroll in only one part. ;


Study Design


NCT number NCT05378893
Study type Interventional
Source Zhejiang Doer Biologics Co., Ltd.
Contact Senior Clinical Operations Director
Phone +86 151 94 40 28 68
Email yg@doerbio.com
Status Recruiting
Phase Phase 1
Start date June 22, 2022
Completion date December 2024